Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI

The IC administration of abciximab bolus acutely decreases CTFC through culprit vessels of patients with ACS undergoing urgent PCI. Further studies evaluating the potential clinical benefits associated with IC abciximab administration are warranted.